Education
About Us
Working with TipRanks
Follow Us
Cellectis S.A. (CLLS)
:CLLS
CLLS Stock Chart & Stats
$3.90
-$0.20(-9.46%)
At close: 4:00 PM EST
$3.90
-$0.20(-9.46%)
Day’s Range― - ―
52-Week Range$1.10 - $5.48
Previous CloseN/A
Volume129.50K
Average Volume (3M)104.78K
Market Cap
$341.08M
Enterprise Value$216.87M
Total Cash (Recent Filing)$52.24M
Total Debt (Recent Filing)$37.58M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Mar 11, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding72,093,636
10 Day Avg. Volume79,085
30 Day Avg. Volume104,785
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.24
Price to Sales (P/S)3.93
P/FCF Ratio8.35
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue2.88
Enterprise Value/Gross Profit3.29
Enterprise Value/Ebitda-35.74
Forecast
1Y Price Target
$6.00Price Target Upside53.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCellectis presented promising outcomes from their Phase 1 BALLI-01 study with lasme-cel, showing a CR/CRi rate of 56% in a heavily pretreated patient population.
Financial PositionCellectis has approximately $225 million in cash, cash equivalents, restricted cash, and fixed-term deposits.
Product PipelineCellectis plans to report a data update with Eti-cel (UCART20x22) from the NATHALI-01 trial in r/r NHL, which could provide further insights into their product pipeline.
Bears Say
Commercial FeasibilityThere is uncertainty about the commercial feasibility of administering lasme-cel due to the high cost and the requirement for multiple rounds of CAR T and HSCT.
Financial OutlookThe company anticipates cash burn of $28 million.
Trial EnrollmentThere is uncertainty about the pace of enrollment in the pivotal Phase 2 trial for lasme-cel.
Cellectis SA News
CLLS FAQ
What was Cellectis S.A.’s price range in the past 12 months?
Cellectis S.A. lowest stock price was $1.10 and its highest was $5.48 in the past 12 months.
What is Cellectis S.A.’s market cap?
Cellectis S.A.’s market cap is $341.08M.
When is Cellectis S.A.’s upcoming earnings report date?
Cellectis S.A.’s upcoming earnings report date is Mar 11, 2026 which is in 90 days.
How were Cellectis S.A.’s earnings last quarter?
Cellectis S.A. released its earnings results on Nov 07, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.232 by $0.242.
Is Cellectis S.A. overvalued?
According to Wall Street analysts Cellectis S.A.’s price is currently Undervalued.
Does Cellectis S.A. pay dividends?
Cellectis S.A. does not currently pay dividends.
What is Cellectis S.A.’s EPS estimate?
Cellectis S.A.’s EPS estimate is -0.32.
How many shares outstanding does Cellectis S.A. have?
Cellectis S.A. has 72,093,636 shares outstanding.
What happened to Cellectis S.A.’s price movement after its last earnings report?
Cellectis S.A. reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.232. Following the earnings report the stock price went up 11.285%.
Which hedge fund is a major shareholder of Cellectis S.A.?
Currently, no hedge funds are holding shares in CLLS
Cellectis SA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (53.85% Upside)
$6.00 (53.85% Upside)
Blogger Sentiment
Bullish
CLLS Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.18%
12-Months-Change
Fundamentals
Return on Equity
-31.07%
Trailing 12-Months
Asset Growth
-13.35%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cellectis S.A.
Cellectis SA is a clinical-stage biotechnology company focused on developing innovative gene-editing technologies to improve the treatment of cancer and other genetic diseases. The company specializes in cell and gene therapies using its proprietary TALEN technology, which allows for precise modifications of DNA. Cellectis operates primarily in the biopharmaceutical sector, developing allogeneic CAR T-cell therapies and gene-edited stem cell therapies for various hematological and solid tumors.
CLLS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment, driven by progress in clinical trials and strategic partnerships, despite financial and legal challenges. The successful advancement of pivotal trials and the strong collaboration with AstraZeneca are significant positives. However, the arbitration with Servier presents a notable uncertainty.View all CLLS earnings summariesCLLS Stock 12 Month Forecast
Average Price Target
$6.00
▲(53.85% Upside)
Technical Analysis
Cartesian Therapeutics
―
Foghorn Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Zura Bio
―
Ownership Overview
―
Insiders
0.63% Mutual Funds
10.93% Other Institutional Investors
88.44% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---